Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 15;116(16):3830-4.
doi: 10.1002/cncr.25247.

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

Elias Jabbour  1 , Guillermo Garcia-Manero, Nicolas Batty, Jenny Shan, Susan O'Brien, Jorge Cortes, Farhad Ravandi, Jean-Pierre Issa, Hagop Kantarjian
Affiliations

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

Elias Jabbour et al. Cancer. .

Abstract

Background: The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known.

Methods: Data from 87 patients with MDS (n=67) and chronic myelomonocytic leukemia (n=.20) after failure of decitabine regimens were reviewed.

Results: After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%. The estimated 12-month survival rates were 27%, 33%, and 33%, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P=.99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P=.01).

Conclusions: The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES

The authors have received financial support from the Betty Foster Leukemia Research Fund. These funds were used to help defray the cost for research nurses.

Figures

Figure 1
Figure 1
Overall survival after decitabine failure is shown (A) overall, (B) by the International Prognostic Scoring System (IPSS), and (C) by The University of Texas M. D. Anderson Cancer Center risk model. MDS indicates myelodysplastic syndrome; AML, acute myeloid leukemia.
Figure 2
Figure 2
Outcome after decitabine failure is shown (n = .87). AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; ET, experimental therapies; NT, no therapy; IA, idarubicin and cytarabine; ASCT, allogeneic stem cell transplantation; UT, unknown therapy; CR, complete remission; mCR, (bone) marrow complete remission; HI, hematologic improvement.
See this image and copyright information in PMC

References

    1. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodys-plastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429–2440. - PubMed
    1. Fenaux P, Mufti G, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional cure regimens (CCR): results of the AZA-001 phase III study [abstract] Blood. 2007;110:250a. Abstract 817.
    1. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–1803. - PubMed
    1. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52–57. - PubMed
    1. Kantarjian HM, O’Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007;109:1133–1137. - PMC - PubMed

MeSH terms